A landmark Swedish study has found that women using the combined oral contraceptive pill have a 71% higher risk of developing depression in their first two years of use, casting new light on a long-simmering health concern. The research, which analysed data from over 264,000 women in the UK Biobank, offers some of the strongest statistical evidence yet of a significant association, particularly for teenagers.
The Weight of the Evidence
Published in 2023, the study indicated that the heightened risk was most acute among adolescents, with women who started the pill as teenagers showing a 130% higher incidence of depressive symptoms. For adult users, the increased incidence was 92%. Separate analysis of the same biobank data has suggested an even higher risk, at 79%. Researchers theorise that teenagers may be more vulnerable because their brains are still developing and are more sensitive to the hormonal fluctuations introduced by external contraception.
However, establishing a definitive causal link remains complex. A challenge for researchers is the “healthy user bias,” where women who experience severe mood effects are more likely to stop taking the pill, thus potentially skewing long-term study results. While some meta-analyses have not found clear evidence that the pill causes increased depressive symptoms in adults, other research, including sibling analyses designed to control for genetic and environmental factors, has provided further support for a causal effect.
The evidence extends beyond combined pills. Some studies have indicated a 34% increased likelihood of depression for users of progestogen-only pills (“mini-pills”), with teens again at higher risk. Norethisterone, a progestogen-based medication taken to delay periods, is also known to potentially cause low mood and anxiety.
A Personal History of Dismissal
This scientific debate often feels distant from the reality in GP surgeries, where patients reporting mood changes can feel dismissed. One woman, who first went on the pill at 15 for debilitating period pain, recalls her doctor’s response years later when she refused a repeat prescription, citing depression: “‘Depressed? That’s not a symptom that’s usually reported,’ he replied.”
Her experience mirrors that of many. Initially pleased with lighter, regulated periods, she soon felt a profound dulling of her emotions, a disconnect from reality she attributed to teenage life. Over several years, she tried four different types of pill, battling low mood with therapy and antidepressants, never connecting it directly to her contraception because it was never presented as a common side effect.
It was only after stopping the pill at 20 that she felt a “darkness had lifted.” A later, brief use of Norethisterone triggered an immediate return of depressive feelings, confirming her suspicions. While she still experiences low moods, she describes the depression linked to hormonal medication as being “on a different level.” Conversations with her mother and friends revealed similar, often unspoken, experiences.
The Contradiction in Clinical Guidance
This personal testimony points to a contradiction between emerging research and some clinical guidelines. The Faculty of Sexual and Reproductive Healthcare (FSRH) states there is no clear, consistent evidence that progestogen-only pills cause depression. Yet the same guidelines advise an “individualised approach,” acknowledging some individuals report mood changes and suggesting healthcare professionals explore other factors and consider alternatives.
This gap may explain why a patient can feel unheard. The National Institute for Health and Care Excellence (NICE) recommends GPs discuss contraception with women who have a history of mental health problems, covering how treatments might interact. Furthermore, the World Health Organisation (WHO) recommends personalised contraceptive counselling that integrates mental health considerations, recognising that choice impacts overall wellbeing.
Public awareness is growing. Google searches on the topic have increased in the UK, and media investigations, including a 2023 documentary fronted by Davina McCall and a 2017 investigation by The Debrief and BBC Woman’s Hour, have called for more research and better NHS processes. This scrutiny coincides with a decline in pill use in England, where community pharmacy dispensations fell from 8.5 million items in 2014/2015 to 7.2 million in 2022/2023.
The Ongoing Search for Solutions
For the woman at the heart of this story, the dilemma persists. Her painful, irregular periods remain undiagnosed despite tests and scans. She has been advised by another GP to “stay fit and active” and to return only if she struggles to conceive in future.
Her experience underscores the difficult balance many face. Hormonal contraception, including the pill, hormonal coils, implants, and injections, is a first-line medical treatment for painful, heavy, or irregular periods—conditions which can stem from issues like endometriosis, adenomyosis, or PCOS. Non-hormonal options for pain management include over-the-counter painkillers like ibuprofen, heat pads, and tranexamic acid for heavy bleeding.
The core issue, as highlighted by both the data and the patient’s journey, is the need for informed, individualised choice. With research suggesting a tangible risk, particularly for young women, the medical conversation is evolving. The hope for many is that future patients will not have to choose between managing physical pain and safeguarding their mental health, and that their concerns will be met with both empirical evidence and empathetic listening.